Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities
Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities
Feb 09
christian1

Exiris @ Presa Diretta

  • 9th February 2016
  • News

Presa Diretta, the broadcast reporting on the Italian hottest news, interviews Exiris CSO on pharmaceutical research and drugs costs, and on the potential spreading benefits that can raise from the collaboration between private and public research, with Exiris presenting itself as a model of this private/public synergy aimed at increasing the probability of success and decreasing the costs of drug research.

Broadcast on March 13th 2016.

 

  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • E-Mail

Comments are closed.

Latest News

  • Interview with Paola Gallinari on “Osservatorio medico-scientifico”
  • Exiris @ RaiNews24
  • Exiris presents a “High Complexity-High Efficiency Human Antibody Phage Display Library” at the Festival of Biologics (FOB) 2019, Basel 15-17 October 2019
  • Exiris receives European Union research grant for the ETN MAGICBULLET RELOADED project
  • New data presented at the 35th European Peptide Symposium, 35EPS, Dublin 26th-31st August 2018
  • New data presented at the Peptides and Conjugates for Tumor Targeting, Therapy and Diagnosis, Riminipeptide2018 Congress
  • Exiris is awarded a grant from Regione Lazio LIFE 2020
  • Exiris files patent application on novel cancer therapeutic antibodies
  • New data presented at the 7th Annual World ADC Berlin 2017
  • Exiris @ Presa Diretta
© 2016 Exiris Srl · P.IVA 10897561006